New protein discovery may widen drug design optionsFebruary 13th, 2008 - 4:29 pm ICT by admin
Washington, February 13 (ANI): An important family of proteins known to function at the cell surface also functions at a site within the cell, say researchers.
The findings by researchers at the University of North Carolina at Chapel Hill have potential implications for drug development because they involve G protein-coupled receptors (GPCRs), which are the target of 40 to 50 per cent of modern medicinal drugssuch as antihistamines and drugs for high blood pressure.
In humans, reactions to everything from taste and smell to stimulants like adrenaline or caffeine requires G-protein signalling.
So far, the only known way to turn on a G-protein was through a receptor sitting on a cells surface membrane, which accepts outside signals and relays them inside the cell.
Henrik Dohlman, a professor of Biochemistry and Biophysics, believes that discovering a protein that activates G-proteins from inside a cell may open up an entirely new pathway for drug development.
No drug is 100 percent effective, 100 percent free of side effects and 100 percent safe. The more options we have biochemically, the more selective we can be in designing new drugs. If we can find another way of modulating G-proteins, we could expand the drug targets that are available to pharmacology, said Dohlman, senior author of the study published online in the journal Current Biology
Mike Lee, a graduate student in the UNC School of Medicines department of pharmacology, identified the new protein called Arr4 in yeast cells. He employed a mutant form of G-protein to search for any messengers inside the yeast cell with an affinity for G-proteins.
We went looking for things that could activate G-proteins but dont resemble known receptors, Lee said.
He identified seven proteins that werent receptors, but did bind to G-proteins.
The researcher then moved on to carry out further tests on one of the seven proteins, Arr4, to determine its function.
He found that in yeast, Arr4 was involved in cell fusion, a process in which two yeasts fuse together to form one cell by combining their genetic data.
While a G-protein coupled receptor (GPCR) controls cell fusion, Arr4 appears to play a supporting role, Lee says.
According to him, Arr4 may allow the cell to go through several additional rounds of signal activation without needing to go back to the receptor.
Our current thinking is its not so much that this is the ignition for signaling, its more like an overdrive. Once the pathway is activated by the hormone outside, Arr4 sustains the activity inside. What we dont know is if Arr4 is itself simulated by some signal, and of course were very interested in finding out if thats the case, Lee said. (ANI)
Tags: cell surface, current biology, design options, drug targets, g protein coupled receptors, g proteins, gpcrs, high blood pressure, medicines department, new drugs, north carolina at chapel, north carolina at chapel hill, protein coupled receptors, protein discovery, surface membrane, target, unc school, university of north carolina at chapel hill, yeast cell, yeast cells